Longboard Pharmaceuticals/LBPH

$17.44

-3.16%
-
1D1W1MYTD1YMAX

About Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Ticker

LBPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kevin Lind

Employees

50

Headquarters

La jolla, United States

LBPH Metrics

BasicAdvanced
$628.33M
Market cap
-
P/E ratio
-$2.39
EPS
-
Beta
-
Dividend rate
$628.33M
$28.15
$3.60
599.17K
5.138
-89.72%
-106.3%
-105.91%
10.448
15.354
6.66%

What the Analysts think about LBPH

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
138.7% upside
High $60.00
Low $30.00
$17.44
Current price
$41.63
Average price target

LBPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-15M
16.28%
Profit margin
0%
-

LBPH Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.8%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.56
-$0.65
-$0.55
-$0.62
-
Expected
-$0.57
-$0.60
-$0.70
-$0.60
-$0.49
Surprise
-2.49%
9.11%
-21.87%
3.8%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Longboard Pharmaceuticals stock?

Longboard Pharmaceuticals (LBPH) has a market cap of $628.33M as of April 22, 2024.

What is the P/E ratio for Longboard Pharmaceuticals stock?

The price to earnings (P/E) ratio for Longboard Pharmaceuticals (LBPH) stock is 0 as of April 22, 2024.

Does Longboard Pharmaceuticals stock pay dividends?

No, Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders as of April 22, 2024.

When is the next Longboard Pharmaceuticals dividend payment date?

Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders.

What is the beta indicator for Longboard Pharmaceuticals?

Longboard Pharmaceuticals (LBPH) does not currently have a Beta indicator.

What is the Longboard Pharmaceuticals stock price target?

The target price for Longboard Pharmaceuticals (LBPH) stock is $41.63, which is 138.7% above the current price of $17.44. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Longboard Pharmaceuticals stock

Buy or sell Longboard Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing